These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17598271)

  • 1. [Innovations: from the idea to market readiness].
    Jung M
    Chirurg; 2006 Nov; Suppl():353. PubMed ID: 17598271
    [No Abstract]   [Full Text] [Related]  

  • 2. Germany: financing innovation is the future challenge.
    Schmitt JM
    Med Device Technol; 2004 Jun; 15(5):38-9. PubMed ID: 15285489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where the money is.
    Fitzgerald M
    Nat Biotechnol; 2006 Mar; 24(3):240-2. PubMed ID: 16525370
    [No Abstract]   [Full Text] [Related]  

  • 4. Diversa restructures, raising question over bioprospecting.
    Sheridan C
    Nat Biotechnol; 2006 Mar; 24(3):229. PubMed ID: 16525364
    [No Abstract]   [Full Text] [Related]  

  • 5. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
    Schmidt E
    Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
    [No Abstract]   [Full Text] [Related]  

  • 6. Keeping it real with investors.
    Dipp M; Westphal C; Mirkin C; Baker J; Harper T; Harris C
    Nat Biotechnol; 2006 Feb; 24(2):133-5. PubMed ID: 16526102
    [No Abstract]   [Full Text] [Related]  

  • 7. Medical technology & spending: the next market bubble?
    Dentzer S
    Health Aff (Millwood); 2008; 27(6):1464-5. PubMed ID: 18997200
    [No Abstract]   [Full Text] [Related]  

  • 8. Crystal gazing: biotech's financial outlook: the investment banker's view.
    Strupp DJ
    Nat Biotechnol; 2006 Mar; 24(3):263-4. PubMed ID: 16525375
    [No Abstract]   [Full Text] [Related]  

  • 9. 2006: a stellar year for financing.
    Lawrence S
    Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738
    [No Abstract]   [Full Text] [Related]  

  • 10. Europe needs a single, deep capital market.
    Hodgson J
    Nat Biotechnol; 2002 Oct; 20(10):960-1. PubMed ID: 12355101
    [No Abstract]   [Full Text] [Related]  

  • 11. Venture capital for the pharmacologist.
    Miller LG
    Mol Interv; 2001 Dec; 1(5):242-4. PubMed ID: 14993362
    [No Abstract]   [Full Text] [Related]  

  • 12. Looking at US versus European exit opportunities.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294
    [No Abstract]   [Full Text] [Related]  

  • 13. Mind the (biomedical funding) gap.
    Klausner A
    Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotechs await single European financial market.
    Louët S
    Nat Biotechnol; 2003 Dec; 21(12):1417. PubMed ID: 14647312
    [No Abstract]   [Full Text] [Related]  

  • 15. Life support for life science innovation?
    Nat Biotechnol; 2007 Feb; 25(2):144. PubMed ID: 17287731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2005: biotech partners up.
    Lawrence S
    Nat Biotechnol; 2006 Feb; 24(2):126. PubMed ID: 16465145
    [No Abstract]   [Full Text] [Related]  

  • 17. VC funding hits high in Q1.
    Lawrence S
    Nat Biotechnol; 2007 May; 25(5):496. PubMed ID: 17483825
    [No Abstract]   [Full Text] [Related]  

  • 18. The service-based bioeconomy.
    Nat Biotechnol; 2014 Jul; 32(7):597. PubMed ID: 25004205
    [No Abstract]   [Full Text] [Related]  

  • 19. Hurdles and opportunities for a venture capitalist investing in therapies for orphan retinal diseases.
    Blair JC
    Retina; 2005 Dec; 25(8 Suppl):S105-S108. PubMed ID: 16374312
    [No Abstract]   [Full Text] [Related]  

  • 20. Developing market.
    Taylor W
    Nat Biotechnol; 2004 Sep; 22(9):1075. PubMed ID: 15340463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.